Tariquidar, a prototype of third-generation P-gp inhibitors, has shown the capability to reverse resistance to drugs like doxorubicin and vinblastine in advanced breast cancer (Durante et al. 2017). The gene discussed is PGP; the disease is breast carcinoma.